Bought
Maintained
Sold
Other funds holding IRMD
CCM
VCM
NTCM
Aviva's IRMD Position: Q1 2026 in Review
Aviva reduced its iRadimed (IRMD) stake by 18% in Q1 2026, selling an estimated $93.7K and leaving 4,403 shares worth $424K. The position accounts for ﹤0.01% of the portfolio, ranked #766.
Aviva first reported a position in IRMD in Q1 2022 and has held it in 6 quarters since. The position peaked at $2.08M in Q2 2022. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.
- Aviva held 4,403 shares of iRadimed worth $424K as of Q1 2026.
- Aviva sold 937 iRadimed shares in Q1 2026, an estimated $93.7K.
- iRadimed made up ﹤0.01% of Aviva's portfolio in Q1 2026, its #766 holding.
- Aviva first reported a position in iRadimed in Q1 2022 and has held it in 6 quarters since.
- Aviva's iRadimed position peaked at $2.08M in Q2 2022.
- 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.
Based on Aviva's 13F filing for Q1 2026, filed 14 May 2026.